Exploiting cancer's phenotypic guise against itself: targeting ectopically expressed peptide G-protein coupled receptors for lung cancer therapy

摘要: Lung cancer, claiming millions of lives annually, has the highest mortality rate worldwide. This advocates development novel cancer therapies that are highly toxic for cells but negligibly healthy cells. One effective treatments is targeting overexpressed surface receptors with receptor-specific drugs. The receptors-in-focus in current review G-protein coupled (GPCRs), which often various types tumors. peptide subfamily GPCRs pivot article owing to high affinity and specificity their cognate ligands, proven efficacy peptide-based therapeutics. summarizes ectopically expressed lung namely, Cholecystokinin-B/Gastrin receptor, Bombesin receptor family, Bradykinin B1 B2 receptors, Arginine vasopressin 1a, 1b 2, Somatostatin type 2. autocrine growth pro-proliferative pathways they mediate, distinct tumor-inhibitory effects somatostatin then discussed. next section covers how these may be influenced or 'corrected' through therapeutics (involving agonists antagonists) GPCRs. proceeds on Nano-scaled delivery platforms, enclose chemotherapeutic agents decorated ligands external surface, as an means We conclude potentially evolving a promising form therapy.